| 胡致平,林圣云,沈建平.来那度胺为主的联合化疗方案治疗复发难治性多发性骨髓瘤的临床观察[J].中国肿瘤,2013,22(9):762-764. |
| 来那度胺为主的联合化疗方案治疗复发难治性多发性骨髓瘤的临床观察 |
| Clinical Observation of Lenalidomide-based Combination Chemotherapy for Relapsed or Refractory Multiple Myeloma |
| 投稿时间：2013-04-23 |
| DOI：10.11735/j.issn.1004-0242.2013.09.A019 |
|
 |
| 中文关键词: 复发难治性多发性骨髓瘤 来那度胺 疗效 不良反应 |
| 英文关键词:relapsed or refractory multiple myeloma lenalidomide efficacy toxicity |
| 基金项目: |
|
| 摘要点击次数: 2880 |
| 全文下载次数: 1960 |
| 中文摘要: |
| 摘 要：［目的］观察来那度胺（lenalidomide）为主的联合化疗方案治疗复发难治性多发性骨髓瘤（multiple myeloma，MM）的临床疗效及不良反应。［方法］ 22例复发难治性MM患者中，来那度胺联合马法兰和地塞米松治疗者14例，来那度胺联合地塞米松治疗者7例，来那度胺联合亚砷酸和地塞米松治疗者1例。所有患者于2个疗程后评价疗效及不良反应。［结果］ 22例患者中完全缓解（CR）2例（9.1%）；非常好的部分缓解（VGPR）5例（22.7%）；部分缓解（PR）12例（54.5%）；无效以及死亡3例（13.7%），总有效率为86.3%。不良反应主要包括中性粒细胞减少（54.5%）、血小板减少（72.7%）、乏力（100%）以及继发感染（36.4%）。［结论］ 以来那度胺为主的联合化疗是治疗复发难治性MM的合适治疗方案，近期疗效显著，患者耐受性好。 |
| 英文摘要: |
| Abstract：［Purpose］To observe the clinical efficacy and toxicity of lenalidomide-based combination chemotherapy for relapsed or refractory multiple myeloma.［Methods］ 22 patients were enrolled. 14 patients received LMP regimen(lenalidomide melphalan dexamethasone)，7 patients received LD regimen(lenalidomide dexamethasone).And 1 patient received ALD regimen(LD arsenic trioxide).The efficacy and toxicity were evaluated after 2 cycles.［Results］ 2/22(9.1%) achieved complete remission (CR)，5/22(22.7%)achieved very good part remission(VGPR)，12/22(54.5%) got part remission(PR).13.7%(3/22) got no response(NR)，including death.The overall response(OS)was 86.3%. The main toxicity included neutropenia(54.5%)，thrombocytopenia(72.7%)，fatigue(100%) and infection(36.4%).［Conclusion］ Lenalidomide-based chemotherapy might be a promising and well-tolerated treatment for the relapsed or refractory multiple myeloma. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |